TenderlineUK
Procurement Intelligence
Official OCDS
Find a Tender
complete
Official procurement procedure

Procurement of SARS-CoV-2 Antigen Rapid Qualitative Tests (Self-Tests)

Diagnostic kits
UK
Published value
Not published
Submission deadline Not published
Lots published1
Procurement Executive Summary
AI & Search Synopsis
Generated from official OCDS record
Tenderline Synopsis: Department of Health and Social Care: "Procurement of SARS-CoV-2 Antigen Rapid Qualitative Tests (Self-Tests)". Published status: complete. Published value: Value not published. 1 published lot. Submission deadline not published. See the official notice for participation instructions.
Contracting AuthorityDepartment of Health and Social CareScope & CategoriesNot publishedSubmission Window
complete
No deadline published
Submission GatewayDirect notice routeLegal Basis & RegimeStandard procurementEstimated Value (exc. VAT)Not published
Bidder Intelligence · Authority Profile: Department of Health and Social Care
Market Analytics
View Authority Profile →
Derived from OCDS awards & bid statistics
Published history for Department of Health and Social Care. These figures describe retained records, not a forecast of bids or a measure of buyer bias.
Average Price Reduction
Not availableInsufficient comparable data
Requires at least 5 comparable procedures
Competition Density
11.8Bids / Report
54.4% of reports have one bid
Supplier ConcentrationNo estimate
Insufficient attributable awardsNo concentration estimate available
Payment Terms
Check noticePublished terms
Payment obligations depend on the applicable regime and contract. Consult the official documents.
Coverage: 451 active published awards; 397 bid reports (which may be per lot). Supplier values exclude multi-supplier awards, frameworks and DPS, and use GBP only. They are published award values, not payments. Price reduction compares single-lot, single-award, single-supplier GBP procedures with explicitly non-framework/non-DPS status; increases remain in the average. Unpublished data stays unknown. Awarded suppliers are winners, not all bidders.
Procedure terms
Contracting AuthorityDepartment of Health and Social Care
Procedure methodNot published
Procurement categoryNot published
Statuscomplete
Framework / DPSNot published
CompetitionNot published
Above thresholdNot published
Legal basisNot published
Tender period startsNot published
Clarification deadlineNot published
Electronic submissionNot published
Submission languagesNot published
Published9 Apr 2021, 12:35 BST
Last source update9 Apr 2021, 12:35 BST
Recurring procurementNot published
ClassificationDiagnostic kits
Delivery area
UK
OCIDocds-h6vhtk-02a441
What is being bought
The contract is to purchase Innova SARS-CoV-2 Antigen Rapid Qualitative test kits for self-test use. DHSC is the legal manufacturer of these devices and holds an Exceptional Use Authorisation for self-test from the MHRA, making these the only products currently authorised for use as a Covid-19 self-test kit in the UK. The products are NHS branded and come in packs of 7s
What changed
From the official release history
  1. Status changed to complete
    9 Apr 2021, 12:35 BST
  2. Official notice release published
    9 Apr 2021, 12:35 BST
  3. Buyer information updated
    9 Apr 2021, 12:35 BST
Lots and requirements (1)
Published by the contracting authority
  • Lot 1 · #1
    Individual lot title not published
    cancelled
    Published valueNot published
    The contract is to purchase Innova SARS-CoV-2 Antigen Rapid Qualitative test kits for self-test use. DHSC is the legal manufacturer of these devices and holds an Exceptional Use Authorisation for self-test from the MHRA, making these the only products currently authorised for use as a Covid-19 self-test kit in the UK. The products are NHS branded and come in packs of 7s
    Contract periodNot published
    EligibilityNot published
    Options / renewalNot published
Timeline
  1. Procedure published
    9 Apr 2021, 12:35 BST
  2. Award active
    Not published · Not published
  3. Contract active
    Signed 13 Mar 2021, 00:00 GMT · £1,212,000,018
Commercial outcome and competition
Awards
INNOVA MEDICAL GROUP INC
Not published · Not published · active
Contracts
Contract
£1,212,000,018 · signed 13 Mar 2021, 00:00 GMT · active
Bid statistics
bids: 1 (lot 1)
Buyer and organisations in this procedure

Department of Health and Social Care

Contracting authority GB-FTS-43
View buyer profile
Documents (0)
Official links; attachments are not copied
No data
No linked documents are published
Related procedures (0)
No data
No related procedures published
Planning and rationale
Planning budgetNot published
No-engagement rationaleNot published
Procedure rationale1. On 11 March 2020 the World Health Organisation declared a COVID-19 pandemic with the associated serious risk posed to life.  The UK Government’s response to the national emergency posed by COVID-19 includes the putting in place by it of arrangements for large-scale testing in respect of COVID-19. 2. As part of those arrangements, it needs to acquire products in order to implement the large-scale testing programme necessary to build a profile of the spread of COVID-19 and to prevent further loss of human life, to allow the population to return to work safely.  Relevant to its procurement strategy is the efficient use of lateral flow test devices for self-use throughout the UK. 3. Accordingly the UK government will be fulfilling a significant volume of its overall requirement for home testing by using lateral flow devices developed by Innova. 4. DHSC is satisfied the relevant tests permitting use of the negotiated procedure without prior publication (Regulation 32(2)(b)(ii)) are met:a. The works, supplies or services can be supplied only by a particular economic operator as competition is absent for technical reasons: Innova are the only available supplier of home use lateral flow tests for COVID-19 as there is currently no other supplier whose COVID-19 tests are authorised by the relevant regulator, the Medicines and Healthcare products Regulatory Agency (MHRA), for self-test use in the UK.b. No reasonable alternative or substitute exists: there is currently no other supplier of lateral flow devices that has MHRA authorisation for the self-test use needed to satisfy DHSC’s requirement. c. The absence of competition is not the result of an artificial narrowing down of the parameters of the procurement: this procurement is part of a procurement strategy by the UK government to increase testing capacity to meet demand due to the COVID-19 pandemic as the country exits from lockdown.